Key Takeaways
- Compound: Tirzepatide (5.0-day half-life, GLP-1/GIP dual agonist)
- Protocol length: 16 weeks covering 3 dosing phases
- Steady state: Reached in approximately 3.6 weeks at each dose level
- Split dosing: Multiple injections per week produce more stable drug levels with lower peak-to-trough variation
Tirzepatide Split Dosing: 2x Per Week Protocol
Quick Answer
Tirzepatide has a half-life of 5.0 days. This split-dosing protocol divides the weekly dose into multiple smaller injections, producing more stable blood levels compared to once-weekly dosing. The total weekly dose remains the same, but lower peaks may reduce side effects for some people.
Data computed using GLP3Planner's pharmacokinetic model based on published clinical trial parameters.
Understanding Split-Dose Protocols
A split-dose (or microdosing) protocol divides your total weekly dose into two or more smaller injections spread throughout the week. The total amount of drug per week stays the same. What changes is the peak-to-trough ratio: the difference between the highest and lowest drug levels in your body between injections.
With once-weekly dosing, Tirzepatide levels rise sharply after injection and then decline over the next 5.0 days until the next dose. That creates a pronounced "sawtooth" pattern. By splitting the dose into smaller, more frequent injections, you flatten that pattern. Lower peaks may mean fewer side effects for people who are sensitive to concentration spikes, particularly nausea that tends to correlate with peak drug levels.
No clinical trials have specifically studied split-dosing for Tirzepatide. This approach is based on pharmacokinetic principles and community experience. The PK model below shows the calculated levels for this protocol so you can see the expected peak and trough at each phase. For a deeper look at microdosing, see the Tirzepatide microdosing guide.
Dosing Protocol
| Phase | Weeks | Dose | Frequency | Peak (mg) | Trough (mg) | Syringe Units |
|---|---|---|---|---|---|---|
| 2.5mg/week split | 1-4 | 1.25mg | 2x/week | 3.27 | 2.16 | 12 IU |
| 5mg/week split | 5-8 | 2.5mg | 2x/week | 6.61 | 4.36 | 25 IU |
| 10mg/week split | 9-16 | 5.0mg | 2x/week | 13.36 | 8.81 | 50 IU |
Peak and trough values are modeled using a 5.0-day half-life from published clinical data. See methodology.
What the Numbers Mean
The table above shows modeled drug levels at each phase of this protocol. Here is what each column tells you:
Peak (mg)
The highest amount of Tirzepatide in your body, measured right after an injection at steady state for that dose level. Higher peaks are associated with stronger appetite suppression but also more pronounced side effects, especially nausea.
Trough (mg)
The lowest amount remaining just before your next injection. This is the minimum drug level your body maintains between doses. The trough determines whether you still have therapeutic coverage throughout the dosing interval.
Steady State (~3.6 weeks)
The point where drug accumulation stabilizes. Before steady state, each dose adds more drug than your body eliminates, so levels keep climbing. Once reached, the amount in equals the amount out, and your peaks and troughs become consistent from week to week.
These are population-average estimates based on clinical trial data. Individual levels vary based on body composition, metabolism, and injection site. For a personalized view, enter your actual doses into the Tirzepatide calculator.
Pharmacokinetic Summary
Half-Life
5.0 days
Time for 50% of the drug to be eliminated
Steady State
~3.6 weeks
Time to reach stable peak/trough levels at each dose
Final Peak Level
13.36 mg
Peak drug amount at the 10mg/week split dose
Model Your Own Schedule
Enter your actual doses and timing to see a personalized PK curve with your real data.
Open Tirzepatide CalculatorReconstitution Reference
Based on a 30mg vial with 3mL BAC water (10mg/mL):
| Dose | Syringe Units (U-100) | Volume (mL) |
|---|---|---|
| 1.25mg | 12 IU | 0.12mL |
| 2.5mg | 25 IU | 0.25mL |
| 5.0mg | 50 IU | 0.5mL |
Need a different concentration? Use our reconstitution calculator. For step-by-step instructions, see the Tirzepatide reconstitution guide.
Practical Tips for This Protocol
Split Dosing Technique
Splitting doses requires drawing smaller volumes from a reconstituted vial. Accuracy matters more when the injection volume is small.
- Use higher-concentration vials: With split dosing, each individual injection is a smaller volume. A more concentrated reconstitution (less BAC water) makes it easier to draw the correct amount on an insulin syringe.
- Consistent spacing: For twice-weekly protocols, aim for roughly even spacing (e.g., Monday/Thursday or Tuesday/Friday). The exact days matter less than keeping the interval consistent.
- Comparing peak/trough: The main advantage of split dosing is a flatter concentration curve. If you are not experiencing peak-related side effects on weekly dosing, splitting may not offer meaningful benefit.
- Track your schedule: Use the Tirzepatide calculator to model your exact split protocol and compare it visually to once-weekly dosing.
Common Side Effects
In the SURMOUNT-1 trial, the most common side effects of tirzepatide were gastrointestinal: nausea (24-33%), diarrhea (18-23%), and constipation (17-23%) depending on dose. Most events were mild to moderate and occurred during titration.[3]
Nausea
Most common during the first few days after an injection or dose increase. Smaller meals, bland foods, and staying hydrated can help. Some people find evening injections reduce daytime nausea.
Digestive Changes
Diarrhea or constipation may occur as the drug slows gastric emptying. Adequate fiber, water, and gentle activity help regulate digestion. These effects typically improve within the first 2-3 weeks at each dose.
Reduced Appetite
This is an expected effect, not a side effect. Make sure you are still eating enough protein and nutrients even when appetite is suppressed. Skipping meals entirely can lead to fatigue and muscle loss.
For a comprehensive list including less common effects, see the full Tirzepatide side effects guide.
See Your Own Levels
Enter your actual doses and schedule to get a personalized PK curve.
How This Data Was Computed
Levels are modeled using GLP3Planner's pharmacokinetic engine with a 5.0-day half-life (published clinical trial value). The model uses superposition to calculate how weekly doses accumulate over time. Read the full methodology, including clinical data sources and model limitations.
Frequently Asked Questions
How long does Tirzepatide stay in your system?
Tirzepatide has a half-life of 5.0 days. After your last dose, the drug takes approximately 5 half-lives (25 days) to drop below 3% of peak levels. During this time, effects gradually diminish as the drug clears. Use the Tirzepatide calculator to model washout from your specific dose.
What is steady state for Tirzepatide?
Steady state is when drug accumulation stabilizes, meaning the amount entering your system each dose roughly equals the amount eliminated between doses. For Tirzepatide, this takes approximately 3.6 weeks of consistent dosing at the same level. Once at steady state, your peak and trough levels become predictable from week to week.
Is split dosing as effective as once-weekly injection?
The total weekly dose determines average blood levels and overall exposure, which should be similar regardless of how the dose is divided. However, no clinical trials have compared split-dosing to once-weekly for Tirzepatide specifically. The approach is based on pharmacokinetic modeling and community experience.
How accurate is the pharmacokinetic data on this page?
The data uses population-average parameters from published clinical trials. Individual drug levels vary based on body composition, metabolism, kidney and liver function, and injection site. The model is most useful for understanding accumulation patterns, steady state timing, and comparing dosing approaches rather than predicting exact personal blood levels. See the full methodology for details.
What is the peak-to-trough ratio and why does it matter?
The peak-to-trough ratio measures how much drug levels fluctuate between injections. A ratio of 4:1 means your peak is four times your trough. Higher ratios mean bigger swings, which some people associate with more side effects at peak and reduced coverage at trough. Split dosing reduces this ratio by producing smaller, more frequent peaks.
Can I use this data to plan my own dosing schedule?
This data is for informational and educational purposes. It shows modeled drug levels for a specific protocol, which can help you understand what to expect and have informed conversations with your doctor. For a schedule tailored to your exact doses, use the interactive Tirzepatide calculator.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. PubMed
- Novo Nordisk. Ozempic (semaglutide) prescribing information. U.S. Food and Drug Administration. FDA Label
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. U.S. Food and Drug Administration. FDA Label
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400(10366):1869-1881. PubMed
- StatPearls. Pharmacokinetics, Steady State. National Center for Biotechnology Information. NCBI Bookshelf
Medical Disclaimer
This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or recommendations. The pharmacokinetic data shown is modeled from population-average clinical trial parameters and does not predict individual drug levels. Always consult your doctor before starting, adjusting, or stopping any medication.
Related Articles
Tirzepatide Dosing Guide
Complete titration schedule with clinical trial data and side effects management.
Tirzepatide Reconstitution Guide
Step-by-step reconstitution instructions with calculator.
Tirzepatide Side Effects
Common and serious side effects with management strategies.
Tirzepatide Hub
Everything about Tirzepatide in one place: mechanism, trials, dosing, calculators.
PK Methodology
How GLP3Planner calculates drug levels, with clinical data sources.